We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sensyne Health Plc | LSE:SENS | London | Ordinary Share | GB00BYV3J755 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.35 | 0.30 | 0.40 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSENS
RNS Number : 1561L
Sensyne Health PLC
11 January 2021
Notice of Interim Results
Oxford, UK; 11 January 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company") , the Clinical AI company, will announce its Interim Results for the 6 months ended 31 October 2020 on Thursday 21 January 2021.
Lord (Paul) Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will host a virtual briefing for analysts and investors at 13:00 GMT on the day of the results.
Details of the webcast, and the presentation slides, will be available via the Company website. For more details please contact CSCSensynehealth@consilium-comms.com.
-ENDS-
For more information please contact:
Hot Features
Premium
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Michael Norris, Interim Chief Financial
Officer
Dr Richard Pye, Chief Investment Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications +44 (0) 7780600290
Mary-Jane Elliott
Sukaina Virji
Davide Salvi
CSCSensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORSFFFMSEFSEIF
(END) Dow Jones Newswires
January 11, 2021 02:00 ET (07:00 GMT)
1 Year Sensyne Health Chart |
1 Month Sensyne Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
